Minnesota Medical Technologies announced that it has raised $20.6 million in a Series A preferred equity financing to accelerate the commercialization of its fecal incontinence treatment device, StaySure, in the United States.
The funding round was co-led by HM Venture Partners and Southeast Minnesota Capital Partners. The company said the capital will support the launch of its device in the U.S. market, expand its team, and strengthen its financial position as it scales operations.
Minnesota Medical Technologies plans to use the funding to build operational, commercial, and distribution infrastructure needed for the nationwide rollout of StaySure. The company also intends to recruit talent across sales, marketing, and customer care to increase market penetration, boost physician and patient education, and drive brand awareness.
Founded in 2015, Minnesota Medical Technologies focuses on developing continence care products aimed at addressing fecal incontinence, also known as accidental bowel leakage. The condition affects more than 2% of the global population, leaving tens of millions of people worldwide relying primarily on adult diapers and absorbent pads rather than restorative treatments.
The company developed StaySure in collaboration with Mayo Clinic gastroenterologist Adil Bharucha, MD. The device is designed as a simple, single-use insert intended to offer patients a discreet and effective alternative to traditional absorbent products and invasive surgical treatments.
Following clinical testing at Mayo Clinic, the U.S. Food and Drug Administration granted clearance for StaySure in July 2025 through the 510(k) pathway. With regulatory approval secured, Minnesota Medical Technologies is now preparing to scale distribution and commercial adoption of the product across the U.S. healthcare market.
Company leadership said the financing will also be used to reduce debt and provide additional financial stability as the organization expands production and market reach.
The company’s leadership team includes executives with experience from Rochester Medical Corporation, which was acquired by CR Bard for $262 million in 2013.
Minnesota Medical Technologies believes the new funding will enable it to accelerate physician and patient education initiatives, expand distribution channels, and unlock broader adoption of its solution in a large but underserved market for fecal incontinence treatments.
KEY QUOTES
“This funding marks a pivotal moment for our company. With the support of our investors, we are now positioned to launch StaySure™ into the newly cleared US market and expand our talented team. For the millions of people living with fecal incontinence, this represents an opportunity to finally access a safe, effective, and life-changing solution.”
David A. Jonas, CEO and President, Minnesota Medical Technologies Corporation
